Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Authors

Showing 4 results for author "Kumar Anmol".

Back to authors

Thumbnail for Clinical Outcomes Following Ibrutinib Withdrawal in Mantle Cell Lymphoma: A TriNetX Analysis

MCL - 1233

Clinical Outcomes Following Ibrutinib Withdrawal in Mantle Cell Lymphoma: A TriNetX Analysis

Kumar Anmol

Poster Presenter: Kumar Anmol

Thumbnail for Pirtobrutinib-First vs Brexucabtagene Autoleucel-First Sequencing Post Covalent BTK Inhibitor Failure in Mantle Cell Lymphoma: A Propensity-Matched Real-World Analysis

MCL - 1257

Pirtobrutinib-First vs Brexucabtagene Autoleucel-First Sequencing Post Covalent BTK Inhibitor Failure in Mantle Cell Lymphoma: A Propensity-Matched Real-World Analysis

Kumar Anmol

Poster Presenter: Kumar Anmol

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

Thumbnail for Comparative Outcomes With Luspatercept Versus Erythropoiesis-Stimulating Agents in Lower-Risk Myelodysplastic Syndromes: A Propensity Score-Matched Retrospective Cohort Study

MDS - 1271

Comparative Outcomes With Luspatercept Versus Erythropoiesis-Stimulating Agents in Lower-Risk Myelodysplastic Syndromes: A Propensity Score-Matched Retrospective Cohort Study

Kumar Anmol

Poster Presenter: Kumar Anmol

Thumbnail for Survival and Toxicity Outcomes With Hypomethylating Agent Plus Venetoclax vs Hypomethylating Agent Alone in Higher-Risk Myelodysplastic Syndrome: A Propensity-Matched Retrospective Cohort Study

MDS - 1311

Survival and Toxicity Outcomes With Hypomethylating Agent Plus Venetoclax vs Hypomethylating Agent Alone in Higher-Risk Myelodysplastic Syndrome: A Propensity-Matched Retrospective Cohort Study

Kumar Anmol

Poster Presenter: Kumar Anmol

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors